Literature DB >> 31478099

Increased levels of circulating fibroblast growth factor 21 in children with Kawasaki disease.

Yue Peng1,2, Qiongfei Pei1,2, Siqi Feng1,2, Ya Su1,2, Ruixi Liu3, Qijian Yi4, Pengfei Guo5.   

Abstract

The purpose of this study was to examine the serum levels of fibroblast growth factor 21 (FGF21) in children with acute Kawasaki disease (KD) and to investigate its relationship with coronary artery lesions (CALs). Blood samples from 58 children with KD before intravenous immunoglobulin treatment and from 28 healthy children as control group were collected. Serum FGF21 levels in all participants were measured using enzyme-linked immunosorbent assay, and clinical parameters were tested in all KD patients. Serum FGF21 levels were significantly increased in acute KD patients as compared to the control group. Serum levels of FGF21 were substantially higher in the group of KD patients with CALs (KD-CALs) than in KD patients without CALs (KD-NCALs). Positive relationships between serum levels of FGF21 and percentage of leukomonocytes (L %), C-reactive protein, activated partial thromboplastin time and D-dimer were observed in KD patients. Furthermore, serum FGF21 levels were negatively correlated with red blood cell counts, hemoglobin (Hb), percentage of neutrophils (N %) and albumin. Serum level of FGF21 is associated with inflammation and coagulation. The paradoxical increase in serum FGF21 in acute KD patients may indicate a protective compensatory response.

Entities:  

Keywords:  Blood coagulation; Clinical parameters; Coronary arterial lesions (CALs); Fibroblast growth factor 21 (FGF21); Kawasaki disease (KD)

Mesh:

Substances:

Year:  2019        PMID: 31478099     DOI: 10.1007/s10238-019-00577-4

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  43 in total

Review 1.  Evolution of the Fgf and Fgfr gene families.

Authors:  Nobuyuki Itoh; David M Ornitz
Journal:  Trends Genet       Date:  2004-11       Impact factor: 11.639

Review 2.  Energy, evolution, and human diseases: an overview.

Authors:  Jesse Roth; Alessandra L Szulc; Ann Danoff
Journal:  Am J Clin Nutr       Date:  2011-02-02       Impact factor: 7.045

3.  The relationship of fibroblast growth factors 21 and 23 and α-Klotho with platelet activity measured by platelet volume indices.

Authors:  Yoshihiro Takeda; Shu-ichi Fujita; Toshiyuki Ikemoto; Yoshikatsu Okada; Koichi Sohmiya; Masaaki Hoshiga; Nobukazu Ishizaka
Journal:  Clin Chem Lab Med       Date:  2015-09-01       Impact factor: 3.694

4.  Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease.

Authors:  Cedric Manlhiot; Kyle Millar; Fraser Golding; Brian W McCrindle
Journal:  Pediatr Cardiol       Date:  2009-12-19       Impact factor: 1.655

Review 5.  Kawasaki disease. With particular emphasis on arterial lesions.

Authors:  S Naoe; K Takahashi; H Masuda; N Tanaka
Journal:  Acta Pathol Jpn       Date:  1991-11

6.  Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients.

Authors:  H Kato; T Sugimura; T Akagi; N Sato; K Hashino; Y Maeno; T Kazue; G Eto; R Yamakawa
Journal:  Circulation       Date:  1996-09-15       Impact factor: 29.690

7.  Fibroblast growth factor 21 protects against high glucose induced cellular damage and dysfunction of endothelial nitric-oxide synthase in endothelial cells.

Authors:  Xiao-Mei Wang; Shuang-Shuang Song; Hang Xiao; Pan Gao; Xue-Jun Li; Liang-Yi Si
Journal:  Cell Physiol Biochem       Date:  2014-08-13

Review 8.  The emerging role of adipokines as mediators of inflammation and immune responses.

Authors:  Francisca Lago; Carlos Dieguez; Juan Gómez-Reino; Oreste Gualillo
Journal:  Cytokine Growth Factor Rev       Date:  2007-05-15       Impact factor: 7.638

9.  Correlation between NF-κB signal pathway-mediated caspase-4 activation and Kawasaki disease.

Authors:  Jing Tian; Xinjiang An; Ling Niu
Journal:  Exp Ther Med       Date:  2017-04-28       Impact factor: 2.447

Review 10.  Usefulness of the Adipokines as Biomarkers of Ischemic Cardiac Dysfunction.

Authors:  Larisa-Diana Mocan Hognogi; Cerasela-Mihaela Goidescu; Anca-Daniela Farcaş
Journal:  Dis Markers       Date:  2018-10-10       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.